

API PRODUCT PORTFOLIO

PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
Arformoterol tartrate^P polymorph A and D	COPD		US-CN DMF
Formoterol fumarate	Asthma and COPD	√	CEP / US-JP-KR-CN DMF
Glycopyrronium bromide^P	COPD	√	CEP / US-CN DMF
Indacaterol maleate^P	Asthma and COPD	√	EU/US DMF
Salmeterol xinafoate^P	Asthma and COPD	√	CEP / US-CN-KR DMF
Tiotropium Bromide	COPD	√	CEP / US-CN DMF

API PRODUCT PIPELINE

PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
Abediterol	Asthma and COPD			2023	2023
Aclidinium bromide	COPD	√	√	Q3 2020	Q1 2021
Batefenterol	COPD			2023	2024
Olodaterol^P	COPD	√	√	Q3 2020	Q1 2022
Revefenacin	COPD			Q2 2021	Q4 2021
Umeclidinium bromide	COPD	√	√	Q4 2020	Q3 2021
Vilanterol	Asthma and COPD	√	√	√	Q3 2020

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.